PC
ENTA icon

PointState Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

PointState Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,500
Closed -$1.01M – 91
2021
Q4 		$1.01M Buy
+13,500
New +$1.06M 0.02% 112

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PointState Capital's ENTA Position: Q1 2022 in Review

PointState Capital sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 13,500 shares — an estimated $1.01M sold.

PointState Capital first reported a position in ENTA in Q4 2021 and held it in 1 quarter. The position peaked at $1.01M in Q4 2021. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • PointState Capital reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • PointState Capital sold 13,500 Enanta Pharmaceuticals shares in Q1 2022, an estimated $1.01M.
  • PointState Capital first reported a position in Enanta Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • PointState Capital's Enanta Pharmaceuticals position peaked at $1.01M in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.